Ask AI
Back Back
TROP2 ADCs in MBC

CE / CME

Optimizing Management of HER2-Negative MBC: Experts Discuss the Now and Future Roles of TROP-2–Directed ADCs

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

European Learners: 1.00 EBAC® CE Credit

Released: November 14, 2025

Expiration: May 13, 2026

Javier Cortes
Javier Cortes, MD, PhD
Sara M. Tolaney
Sara M. Tolaney, MD, MPH
CME/CE Information

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
Continue to Activity
1.

Patient Case: 54-Yr-Old Woman With Recurrent TNBC



  • 54-yr-old woman with a history of cT2N1 grade 3 IDC of left breast that is ER negative (<1%), PR negative (<1%), HER2 negative (IHC 1+/FISH ratio 1.1) received preoperative therapy with paclitaxel/carboplatin/pembrolizumab → doxorubicin/cyclophosphamide/ pembrolizumab with an excellent clinical response

  • She underwent surgery with a lumpectomy and SN biopsy and was found to have 1.1 cm of residual disease in the breast with 1 positive node

  • She received adjuvant capecitabine + pembrolizumab and 14 mo later developed discomfort in her right flank

  • Imaging revealed liver and lung metastases

  • Liver biopsy was consistent with her original breast primary: ER <1%, PR <1%, HER2 IHC 1+

  • PD-L1 testing was done on the liver biopsy with the 22C3 antibody and returns CPS 2

What is the best treatment option for this patient?

2.

Patient Case: 59-Yr-Old Woman With Metastatic ER+ Breast Cancer



  • 59-yr-old woman with de novo metastatic breast cancer

    • ER 80%, PR 40%, HER2 IHC 1+ 



  • She received prior therapy with AI + CDK4/6 inhibitor → fulvestrant + capivasertib → trastuzumab deruxtecan

  • Prior genomic testing had revealed ESR1 wild-type, PI3K mutation–positive disease

What is the best treatment option for this patient?

3.

Patient Case: 62-Yr-Old Woman With Previously Pretreated ER+/HER2- (IHC 0) MBC



  • 62-yr-old woman with history of a cT4N0 grade 2 IDC of right breast that is ER positive (80%), PR negative (<1%), HER2 negative (IHC 0) received preoperative therapy with → doxorubicin/cyclophosphamide and achieved a partial response

  • She underwent surgery with a mastectomy and SN biopsy and was found to have 6.5 cm of residual disease in the breast with no positive nodes. ER 70%, PR negative, HER2 IHC 0

  • She received adjuvant letrozole and RTE 

  • 3 yr later, imaging revealed liver and bone metastases; liver biopsy was consistent with her original breast primary, ER 70%, PR 5%, HER2 IHC 0, PIK3CA wild type

  • She received fulvestrant and abemaciclib for 10 mo

  • She experienced progressive liver metastases and then received capecitabine for 7 mo → datopotamab deruxtecan with stomatitis prophylaxis adherence

  • However, she developed grade 2 stomatitis on datopotamab deruxtecan

For this patient, which of the following would you recommend as the best management strategy for Dato-DXd–associated stomatitis assuming prophylaxis adherence?

Continue to Activity